Valuation: Summit Therapeutics Inc.

Market Cap 7.82B 10.66B 9.13B 8.56B 14.75B 1,016B 14.9B 101B 39.3B 513B 40.02B 39.15B 1,698B P/E 2026 *
-11x
P/E 2027 * -11.3x
Enterprise Value 7.34B 10.01B 8.58B 8.04B 13.86B 955B 14B 94.83B 36.92B 482B 37.59B 36.77B 1,595B EV / Sales 2026 *
2,509x
EV / Sales 2027 * 182x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
1 day+4.95%
1 week+4.21%
Current month+2.61%
1 month-2.20%
3 months-19.61%
6 months-14.80%
Current year-23.61%
1 week 12.22
Extreme 12.22
13.6
1 month 12.07
Extreme 12.07
15.75
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.52
Extreme 1.52
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 54 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 54 11/11/2020
Date Insider Type Main position Quantity % Market Cap.
1/8/26 A Free

Controller/Auditor

30,000 0.0040%
1/2/26 A Free

Director

42,180 0.0057%
1/2/26 A Free

Chief Executive Officer

11,232 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
+4.95%+4.21%-49.14%+650.56% 10.16B
+3.31%-3.70%+61.03%+103.64% 69.06B
+1.74%+1.06%+49.02%+87.38% 63.06B
+1.09%+22.96%+8.55%-3.03% 28.34B
-0.07%-3.56%-3.45%+467.26% 27.07B
+1.34%+9.39%+60.64%+15.80% 25.45B
+3.98%+4.37%+39.47%-14.65% 19.69B
+1.02%+6.43%+269.42%+420.34% 19.19B
+1.91%+1.43%+9.35%+551.53% 15.95B
+3.98%+6.78%+49.66%+157.94% 13.52B
Average +2.18%+4.20%+49.45%+243.68% 29.15B
Weighted average by Cap. +2.06%+3.10%+52.38%+174.81%

Financials

2026 *2027 *
Net sales 2.93M 3.99M 3.42M 3.2M 5.52M 380M 5.58M 37.79M 14.71M 192M 14.98M 14.66M 636M 41.79M 56.98M 48.82M 45.75M 78.86M 5.43B 79.64M 540M 210M 2.74B 214M 209M 9.08B
Net income -692M -944M -809M -758M -1.31B -90.01B -1.32B -8.94B -3.48B -45.41B -3.55B -3.47B -150B -733M -999M -856M -802M -1.38B -95.24B -1.4B -9.46B -3.68B -48.05B -3.75B -3.67B -159B
Net Debt -474M -646M -553M -518M -894M -61.56B -903M -6.12B -2.38B -31.06B -2.42B -2.37B -103B -202M -276M -236M -221M -382M -26.29B -385M -2.61B -1.02B -13.26B -1.04B -1.01B -43.93B
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
25/08/26 $13.36 +4.95% 6,289,691
24/08/26 $12.73 -3.27% 4,390,696
21/08/26 $13.16 +5.87% 7,074,307
20/08/26 $12.43 -5.19% 6,568,692
19/08/26 $13.11 +2.26% 5,431,233
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
9.799GBP
Average target price
21.10GBP
Spread / Average Target
+115.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock